Tekmira Pharmaceuticals (ABUS): aandelenkoers en nieuws

HomepageABUS • NASDAQ

Tekmira Pharmaceuticals

$ 4,26

16 mrt, 08:20:34 GMT-4 · USD · NASDAQ · Disclaimer

AandeelEffect wordt verhandeld in VSHoofdkantoor in VS

Vorige slotkoers

$ 4,26

Jaar-range

$ 2,71 - $ 5,10

Beurswaarde

819,30 mln. USD

Gem. volume

2,67 mln.

Koers/winst

Dividendrendement

Primaire beurs

NASDAQ

Marktnieuws

Yahoo Finance

16 minuten geleden

JFB (NASDAQ: JFB) Announces XTEND and Rayonix Execute Exclusive Manufacturing and Distribution Agreement with Initial $11 Million Commitment to Expand XOS Platform into India.

Fresno Bee

38 minuten geleden

New to The Street Broadcasts Episode Featuring FreeCast (NASDAQ:CAST), KLED.AI, PetVivo (OTCQB:PETV), EmpowerLit, and BlackBarn NYC on Bloomberg Television - March 21 at 6:30 PM EST

Lifecore (NASDAQ: LFCR) lifts margins but guides 2026 revenue below 2025

Trump has 15 days to end the Iran war or markets face a brutal April repricing — from oil to the S&P 500

Severe oil shock could drag S&P 500 down to 5,400, Goldman warns

How do companies get added to (& dropped from) the Dow? The averages committee explained

.DJI

0,00%

Over

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

CEO

William H. Collier

Opgericht

2007

Hoofdvestiging

Warminster, Pennsylvania
Verenigde Staten

Website

arbutusbio.com

Werknemers